Exelixis Announces Results From Expansion Cohort Of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib In Patients With Advanced Kidney Cancer At IKCS 2023
Portfolio Pulse from Benzinga Newsdesk
Exelixis, Inc. (NASDAQ:EXEL) announced initial results from an expansion cohort of STELLAR-001 evaluating zanzalintinib in patients with previously treated clear cell renal cell carcinoma (ccRCC). The results demonstrated an objective response rate of 38% and a disease control rate of 88%. The findings were presented at the 2023 International Kidney Cancer Symposium (IKCS). The results are encouraging for patients with advanced kidney cancer who have exhausted their treatment options.
November 10, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exelixis' zanzalintinib shows promising results in phase 1b trial for patients with advanced kidney cancer. This could potentially open a new treatment option for patients who have exhausted their current options.
The positive results from the trial of zanzalintinib could potentially lead to its approval as a treatment for advanced kidney cancer. This would open a new revenue stream for Exelixis, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100